Loading
Tests whether adding a bispecific to first-line chemotherapy cures more patients up front.
EPCORE DLBCL-2, trial NCT05578976 sponsored by Genmab and AbbVie, tests whether adding a fixed duration of the bispecific epcoritamab to first-line R-CHOP cures more patients with untreated diffuse large B-cell lymphoma up front. Topline results were announced in 2026 and presented at EHA 2026, and together with frontMIND and POLARIX the trial defines the frontline options for higher-risk disease. OnCo links it to lymphoma and epcoritamab. Whether a T-cell engager added to chemotherapy improves cure rates enough to justify its toxicity and cost in the first line is the question its data will answer.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares ctDNA-guided escalation and de-escalation in frontline DLBCL, Epcoritamab, Genmab, T-cell engagers (bispecific).
Shares Epcoritamab, Genmab, T-cell engagers (bispecific), Diffuse large B-cell lymphoma.
Shares ctDNA-guided escalation and de-escalation in frontline DLBCL, Epcoritamab, Genmab, T-cell engagers (bispecific).
Shares ctDNA-guided escalation and de-escalation in frontline DLBCL, Epcoritamab, Genmab, T-cell engagers (bispecific).
Shares Epcoritamab, Genmab, T-cell engagers (bispecific), Diffuse large B-cell lymphoma.
Shares ctDNA-guided escalation and de-escalation in frontline DLBCL, Epcoritamab, Genmab, T-cell engagers (bispecific).
Shares Epcoritamab, Genmab, T-cell engagers (bispecific).
Shares Epcoritamab, Genmab, T-cell engagers (bispecific).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/